Dornase alfa

Dornase alfa
Clinical data
Trade names	Pulmozyme
AHFS/Drugs.com	Monograph
MedlinePlus	a694002
License data	US DailyMed: Dornase alfa;
Pregnancy; category	AU: B1[1];
Routes of; administration	Inhalation
ATC code	R05CB13 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only)[1]; CA: ℞-only / Schedule D[2]; US: ℞-only[3]; In general: ℞ (Prescription only);
Identifiers
CAS Number	143831-71-4 ;
DrugBank	DB00003 ;
ChemSpider	none;
UNII	953A26OA1Y;
KEGG	D03896;
CompTox Dashboard (EPA)	DTXSID801010888 ;
ECHA InfoCard	100.029.685
Chemical and physical data
Formula	C1321H1999N339O396S9
Molar mass	29254.04 g·mol−1
	(what is this?) (verify)

Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.[3] It is produced in Chinese hamster ovary cells.[3]

Medical uses

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.[3]

Society and culture

Legal status

Dornase alfa is an orphan drug.[4]

Research

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.[5][6]

References

Product guildlink.com.au
"Pulmozyme Product information". Health Canada. 25 April 2012. Retrieved 9 January 2023.
"Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.
Collier, Joe (1 September 1995). "Dornase-alfa and orphan drugs". The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID 7651014. S2CID 5456247.
Erdeve O, Uras N, Atasay B, Arsan S (2007). "Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series". Croat Med J. 48 (2): 234–9. PMC 2080511. PMID 17436388.
Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). "DNase and atelectasis in non-cystic fibrosis pediatric patients". Crit Care. 9 (4): R351-6. doi:10.1186/cc3544. PMC 1269442. PMID 16137347.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Pulmozyme_PI-1] Product guildlink.com.au

[2] "Pulmozyme Product information". Health Canada. 25 April 2012. Retrieved 9 January 2023.

[Pulmozyme_FDA_label-3] "Pulmozyme- dornase alfa solution". DailyMed. 21 October 2020. Retrieved 9 January 2023.

[4] Collier, Joe (1 September 1995). "Dornase-alfa and orphan drugs". The Lancet. 346 (8975): 633. doi:10.1016/S0140-6736(95)91460-9. PMID 7651014. S2CID 5456247.

[pmid17436388-5] Erdeve O, Uras N, Atasay B, Arsan S (2007). "Efficacy and safety of nebulized recombinant human DNase as rescue treatment for persistent atelectasis in newborns: case-series". Croat Med J. 48 (2): 234–9. PMC 2080511. PMID 17436388.

[pmid16137347-6] Hendriks T, de Hoog M, Lequin MH, Devos AS, Merkus PJ (2005). "DNase and atelectasis in non-cystic fibrosis pediatric patients". Crit Care. 9 (4): R351-6. doi:10.1186/cc3544. PMC 1269442. PMID 16137347.